Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 23;2(2):CD012158.
doi: 10.1002/14651858.CD012158.pub2.

Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease

Joseph Em van Agteren  1 , Khin Hnin  2 , Dion Grosser  3 , Kristin V Carson  4 , Brian J Smith  4
Affiliations

Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease

Joseph Em van Agteren et al. Cochrane Database Syst Rev. .

Abstract

Background: In the recent years, a variety of bronchoscopic lung volume reduction (BLVR) procedures have emerged that may provide a treatment option to participants suffering from moderate to severe chronic obstructive pulmonary disease (COPD).

Objectives: To assess the effects of BLVR on the short- and long-term health outcomes in participants with moderate to severe COPD and determine the effectiveness and cost-effectiveness of each individual technique.

Search methods: Studies were identified from the Cochrane Airways Group Specialised Register (CAGR) and by handsearching of respiratory journals and meeting abstracts. All searches are current until 07 December 2016.

Selection criteria: We included randomized controlled trials (RCTs). We included studies reported as full text, those published as abstract only and unpublished data, if available.

Data collection and analysis: Two independent review authors assessed studies for inclusion and extracted data. Where possible, data from more than one study were combined in a meta-analysis using RevMan 5 software.

Main results: AeriSealOne RCT of 95 participants found that AeriSeal compared to control led to a significant median improvement in forced expiratory volume in one second (FEV1) (18.9%, interquartile range (IQR) -0.7% to 41.9% versus 1.3%, IQR -8.2% to 12.9%), and higher quality of life, as measured by the St Georges Respiratory Questionnaire (SGRQ) (-12 units, IQR -22 units to -5 units, versus -3 units, IQR -5 units to 1 units), P = 0.043 and P = 0.0072 respectively. Although there was no significant difference in mortality (Odds Ratio (OR) 2.90, 95% CI 0.14 to 62.15), adverse events were more common for participants treated with AeriSeal (OR 3.71, 95% CI 1.34 to 10.24). The quality of evidence found in this prematurely terminated study was rated low to moderate. Airway bypass stentsTreatment with airway bypass stents compared to control did not lead to significant between-group changes in FEV1 (0.95%, 95% CI -0.16% to 2.06%) or SGRQ scores (-2.00 units, 95% CI -5.58 units to 1.58 units), as found by one study comprising 315 participants. There was no significant difference in mortality (OR 0.76, 95% CI 0.21 to 2.77), nor were there significant differences in adverse events (OR 1.33, 95% CI 0.65 to 2.73) between the two groups. The quality of evidence was rated moderate to high. Endobronchial coilsThree studies comprising 461 participants showed that treatment with endobronchial coils compared to control led to a significant between-group mean difference in FEV1 (10.88%, 95% CI 5.20% to 16.55%) and SGRQ (-9.14 units, 95% CI -11.59 units to -6.70 units). There were no significant differences in mortality (OR 1.49, 95% CI 0.67 to 3.29), but adverse events were significantly more common for participants treated with coils (OR 2.14, 95% CI 1.41 to 3.23). The quality of evidence ranged from low to high. Endobronchial valvesFive studies comprising 703 participants found that endobronchial valves versus control led to significant improvements in FEV1 (standardized mean difference (SMD) 0.48, 95% CI 0.32 to 0.64) and scores on the SGRQ (-7.29 units, 95% CI -11.12 units to -3.45 units). There were no significant differences in mortality between the two groups (OR 1.07, 95% CI 0.47 to 2.43) but adverse events were more common in the endobronchial valve group (OR 5.85, 95% CI 2.16 to 15.84). Participant selection plays an important role as absence of collateral ventilation was associated with superior clinically significant improvements in health outcomes. The quality of evidence ranged from low to high. Intrabronchial valvesIn the comparison of partial bilateral placement of intrabronchial valves to control, one trial favoured control in FEV1 (-2.11% versus 0.04%, P = 0.001) and one trial found no difference between the groups (0.9 L versus 0.87 L, P = 0.065). There were no significant differences in SGRQ scores (MD 2.64 units, 95% CI -0.28 units to 5.56 units) or mortality rates (OR 4.95, 95% CI 0.85 to 28.94), but adverse events were more frequent (OR 3.41, 95% CI 1.48 to 7.84) in participants treated with intrabronchial valves. The lack of functional benefits may be explained by the procedural strategy used, as another study (22 participants) compared unilateral versus partial bilateral placement, finding significant improvements in FEV1 and SGRQ when using the unilateral approach. The quality of evidence ranged between moderate to high. Vapour ablationOne study of 69 participants found significant mean between-group differences in FEV1 (14.70%, 95% CI 7.98% to 21.42%) and SGRQ (-9.70 units, 95% CI -15.62 units to -3.78 units), favouring vapour ablation over control. There was no significant between-group difference in mortality (OR 2.82, 95% CI 0.13 to 61.06), but vapour ablation led to significantly more adverse events (OR 3.86, 95% CI 1.00 to 14.97). The quality of evidence ranged from low to moderate.

Authors' conclusions: Results for selected BLVR procedures indicate they can provide significant and clinically meaningful short-term (up to one year) improvements in health outcomes, but this was at the expense of increased adverse events. The currently available evidence is not sufficient to assess the effect of BLVR procedures on mortality. These findings are limited by the lack of long-term follow-up data, limited availability of cost-effectiveness data, significant heterogeneity in results, presence of skew and high CIs, and the open-label character of a number of the studies.

PubMed Disclaimer

Conflict of interest statement

Dion Grosser has received payment to attend workshops and to provide education and proctoring for placement of endobronchial valves (Pulmonx) and has received flights and accommodation to attend an education session on implantation of coils (PneumRx). None of the other review authors are aware of any conflict of interest.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 BLVR to medical therapy, outcome: 1.1 Mortality (All methods, end of follow‐up).
5
5
Forest plot of comparison: 1 BLVR to medical therapy, outcome: 1.2 Adverse Events (all methods, end of follow‐up).
1.1
1.1. Analysis
Comparison 1 BVLR (all methods) versus medical therapy, Outcome 1 Mortality (end of follow‐up, all methods).
1.2
1.2. Analysis
Comparison 1 BVLR (all methods) versus medical therapy, Outcome 2 Adverse events (end of follow‐up, all methods).
2.1
2.1. Analysis
Comparison 2 Endobronchial coils versus medical therapy, Outcome 1 Absolute % change in FEV1 (end of follow‐up, endobronchial coils).
2.2
2.2. Analysis
Comparison 2 Endobronchial coils versus medical therapy, Outcome 2 SGRQ change from baseline (end of follow‐up, endobronchial coils).
2.3
2.3. Analysis
Comparison 2 Endobronchial coils versus medical therapy, Outcome 3 RV change from baseline (L, end of follow‐up, endobronchial coils).
2.4
2.4. Analysis
Comparison 2 Endobronchial coils versus medical therapy, Outcome 4 TLC change from baseline (L, end of follow‐up, endobronchial coils).
2.5
2.5. Analysis
Comparison 2 Endobronchial coils versus medical therapy, Outcome 5 RV/TLC change from baseline (end of follow‐up, endobronchial coils).
2.6
2.6. Analysis
Comparison 2 Endobronchial coils versus medical therapy, Outcome 6 6MWD change from baseline (end of follow‐up, endobronchial coils).
3.1
3.1. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 1 % change in FEV1 (end of follow‐up, endobronchial valves).
3.2
3.2. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 2 % change in FEV1 (stratified per follow‐up, endobronchial valves).
3.3
3.3. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 3 % change in FEV1 (stratified per disease distribution, endobronchial valves).
3.4
3.4. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 4 % Change in FEV1 (stratified by collateral ventilation, endobronchial valves).
3.5
3.5. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 5 Mortality (stratified per follow‐up, endobronchial valves).
3.6
3.6. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 6 Mortality (stratified by collateral ventilation, endobronchial valves).
3.7
3.7. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 7 SGRQ change from baseline (end of follow‐up, endobronchial valves).
3.8
3.8. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 8 SGRQ change from baseline (stratified by follow‐up time, endobronchial valves).
3.9
3.9. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 9 SGRQ change from baseline (stratified by collateral ventilation, endobronchial valves).
3.10
3.10. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 10 RV change from baseline (L, end of follow‐up, endobronchial valves).
3.11
3.11. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 11 TLC change from baseline (L, end of follow‐up, endobronchial valves).
3.12
3.12. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 12 RV/TLC change from baseline (end of follow‐up, endobronchial valves).
3.13
3.13. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 13 6MWD change from baseline (end of follow‐up, endobronchial valves).
3.14
3.14. Analysis
Comparison 3 Endobronchial valves versus medical therapy, Outcome 14 6MWD change from baseline (stratified per collateral ventilation,, endobronchial valves).
4.1
4.1. Analysis
Comparison 4 Intrabronchial valves versus medical therapy, Outcome 1 SGRQ change from baseline (end of follow‐up, intrabronchial valves).
4.2
4.2. Analysis
Comparison 4 Intrabronchial valves versus medical therapy, Outcome 2 RV change from baseline (L, end of follow‐up, intrabronchial valves).
4.3
4.3. Analysis
Comparison 4 Intrabronchial valves versus medical therapy, Outcome 3 TLC change from baseline (L, end of follow‐up, intrabronchial valves).
4.4
4.4. Analysis
Comparison 4 Intrabronchial valves versus medical therapy, Outcome 4 PAO2 (end of follow‐up, intrabronchial valves).
4.5
4.5. Analysis
Comparison 4 Intrabronchial valves versus medical therapy, Outcome 5 PACO2 (end of follow‐up, intrabronchial valves).
4.6
4.6. Analysis
Comparison 4 Intrabronchial valves versus medical therapy, Outcome 6 6MWD change from baseline (intrabronchial valves).
See this image and copyright information in PMC

Update of

References

References to studies included in this review

ASPIRE 2015 {published data only}
    1. Come CE, Kramer MR, Dransfield MT, Abu‐Hijleh M, Berkowitz D, Bezzi M, et al. A randomised trial of lung sealant versus medical therapy for advanced emphysema. European Respiratory Journal 2015;46(3):651‐62. [DOI: 10.1183/09031936.00065715] - DOI - PMC - PubMed
BeLieVeR HIFi 2015 {published data only}
    1. Davey C, Zoumot Z, Jordan S, Carr DH, Polkey MI, Shah PL, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR‐HIFi trial): study design and rationale. Thorax 2015;70(3):288‐90. [DOI: 10.1136/thoraxjnl-2014-205127] - DOI - PMC - PubMed
    1. Davey C, Zoumot Z, Jordan S, McNulty WH, Carr DH, Hind MD, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR‐HIFi study): a randomised controlled trial. Lancet 2015;386(9998):1066‐73. [DOI: 10.1016/S0140-6736(15)60001-0] - DOI - PubMed
Ease 2011 {published data only}
    1. Shah PL, Slebos D‐J, Cardoso PFG, Cetti E, Voelker K, Levine B, et al. Bronchoscopic lung‐volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham‐controlled, multicentre trial. Lancet 2011;378(9795):997‐1005. [DOI: 10.1016/S0140-6736(11)61050-7] - DOI - PubMed
    1. Shah PL, Slebos D‐J, Cardoso PFG, Cetti EJ, Sybrecht GW, Cooper JD. Design of the exhale airway stents for emphysema (EASE) trial: an endoscopic procedure for reducing hyperinflation. BMC Pulmonary Medicine 2011;11(1):1. [DOI: 10.1186/1471-2466-11-1] - DOI - PMC - PubMed
Eberhardt 2012 {published data only}
    1. Eberhardt R, Gompelmann D, Schuhmann M, Reinhardt H, Ernst A, Heussel CP, et al. Complete unilateral vs partial bilateral endoscopic lung volume reduction in patients with bilateral lung emphysema. Chest 2012;142(4):900‐8. [DOI: 10.1378/chest.11-2886] - DOI - PubMed
IBV Valve trial 2014 {published data only}
    1. Wood DE, Nader DA, Springmeyer SC, Elstad MR, Coxson HO, Chan A, et al. The IBV Valve trial: a multicenter, randomized, double‐blind trial of endobronchial therapy for severe emphysema. Journal of Bronchology & Interventional Pulmonology 2014;21(4):288‐97. [DOI: 10.1097/LBR.0000000000000110] - DOI - PubMed
IMPACT 2016 {published data only}
    1. Valipour A, Slebos D‐J, Herth F, Darwiche K, Wagner M, Ficker JH, et al. Endobronchial valve therapy in patients with homogeneous emphysema: results from the IMPACT study. American Journal of Respiratory and Critical Care Medicine 2016;194 (9):1073‐82. [DOI: 10.1164/rccm.201607-1383OC] - DOI - PubMed
Ninane 2012 {published data only}
    1. Ninane V, Bezzi M, Geltner C, Gottlieb J, Seijo L, Munavvar M, et al. Non‐lobar atelectasis approach for the treatment of advanced emphysema with bronchial valves in a European multicenter, single blinded and randomized study. American Journal of Respiratory and Critical Care Medicine 2010;181:A2847.
    1. Ninane V, Bezzi M, Geltner C, Gottlieb J, Seijo L, Munavvar M, et al. The European multicenter, single blinded and randomized study of bronchial valves for the treatment of advanced emphysema: procedural results.. American Journal of Respiratory and Critical Care Medicine 2010;181:A5164.
    1. Ninane V, Geltner C, Bezzi M, Foccoli P, Gottlieb J, Welte T, et al. Multicentre European study for the treatment of advanced emphysema with bronchial valves. European Respiratory Journal 2012;39(6):1319‐25. [DOI: 10.1183/09031936.00019711] - DOI - PubMed
RENEW 2016 {published data only}
    1. Sciurba FC, Criner GJ, Strange C, Shah PL, Michaud G, Connolly TA, et al. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: the RENEW randomized clinical trial. JAMA 2016;315(20):2178‐89. [DOI: 10.1001/jama.2016.6261] - DOI - PubMed
RESET 2015 {published data only}
    1. Shah PL, Zoumot Z, Singh S, Bicknell SR, Ross ET, Quiring J, et al. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respiratory Medicine 2013;1(3):233‐40. [DOI: 10.1016/S2213-2600(13)70047-X] - DOI - PubMed
    1. Zoumot Z, Kemp SV, Singh S, Bicknell SR, McNulty WH, Hopkinson NS, et al. Endobronchial coils for severe emphysema are effective up to 12 months following treatment: medium term and cross‐over results from a randomised controlled trial. PLOS One 2015;10(4):e0122656. [DOI: 10.1371/journal.pone.0122656] - DOI - PMC - PubMed
Revolens 2016 {published data only}
    1. Deslee G, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, et al. Lung volume reduction coil treatment vs usual care in patients with severe emphysema: the REVOLENS randomized clinical trial. JAMA 2016;315(2):175‐84. [DOI: 10.1001/jama.2015.17821] - DOI - PubMed
STELVIO 2015 {published data only}
    1. Hartman JE, Klooster K, Slebos D‐J, Hacken NHT. Improvement of physical activity after endobronchial valve treatment in emphysema patients. Respiratory Medicine 2016;117:116‐21. [DOI: 10.1016/j.rmed.2016.06.009] - DOI - PubMed
    1. Klooster K, Hacken NHT, Hartman JE, Kerstjens HAM, Rikxoort EM, Slebos D‐J. Endobronchial valves for emphysema without interlobar collateral ventilation. New England Journal of Medicine 2015;373(24):2325‐35. [DOI: 10.1056/NEJMoa1507807] - DOI - PubMed
STEP‐UP 2016 {published data only}
    1. Bandyopadhyay S, Henne E, Gupta A, Barry R, Snell G, Strange C, et al. Segmental approach to lung volume reduction therapy for emphysema patients. Respiration 2014;89(1):76‐81. [DOI: 10.1159/000369036] - DOI - PubMed
    1. Herth FJF, Valipour A, Shah PL, Eberhardt R, Grah C, Egan J, et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6‐month results of the multicentre, parallel‐group, open‐label, randomised controlled STEP‐UP trial. Lancet Respiratory Medicine 2016;4(3):185‐93. [DOI: 10.1016/S2213-2600(16)00045-X] - DOI - PubMed
    1. Valipour A, Herth FJF, Eberhardt R, Shah PL, Gupta A, Barry R, et al. Design of the randomized, controlled sequential staged treatment of emphysema with upper lobe predominance (STEP‐UP) study. BMC Pulmonary Medicine 2014;14(1):1. [DOI: 10.1186/1471-2466-14-190] - DOI - PMC - PubMed
VENT EU 2012 {published data only}
    1. Herth FJF, Noppen M, Valipour A, Leroy S, Vergnon J‐M, Ficker JH, et al. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. European Respiratory Journal 2012;39(6):1334‐42. [DOI: 10.1183/09031936.00161611] - DOI - PubMed
    1. Pietzsch JB, Garner A, Herth FJF. Cost‐effectiveness of endobronchial valve therapy for severe emphysema: a model‐based projection based on the VENT study. Respiration 2014;88(5):389‐98. [DOI: 10.1159/000368088] - DOI - PubMed
VENT US 2010 {published data only}
    1. Argula RG, Strange C, Ramakrishnan V, Goldin J. Baseline regional perfusion impacts exercise response to endobronchial valve therapy in advanced pulmonary emphysema. Chest 2013;144(5):1578‐86. - PubMed
    1. Brown MS, Kim HJ, Abtin FG, Strange C, Galperin‐Aizenberg M, Pais R, et al. Emphysema lung lobe volume reduction: effects on the ipsilateral and contralateral lobes. European Radiology 2012;22(7):1547‐55. - PubMed
    1. Eberhardt R, Herth FJF, Radhakrishnan S, Gompelmann D. Comparing clinical outcomes in upper versus lower lobe endobronchial valve treatment in severe emphysema. Respiration 2015;90(4):314‐20. - PubMed
    1. Liberator C, Shenoy K, Marchetti N, Criner G. The role of lobe selection on FEV1 response in endobronchial valve therapy. Journal of Chronic Obstructive Pulmonary Disease 2016;13(4):1‐6. - PubMed
    1. Pietzsch JB, Garner A, Herth FJF. Cost‐effectiveness of endobronchial valve therapy for severe emphysema: a model‐based projection based on the VENT study. Respiration 2014;88(5):389‐98. [DOI: 10.1159/000368088] - DOI - PubMed

References to studies excluded from this review

Abumossalam 2016 {published data only}
    1. Abumossalam AM, El‐Halaby HA, Abd El‐khalek AM. Poor man medical pneumoplasty: bronchoscopic lung volume reduction with hot saline versus dissolved doxycycline as a neoteric remedy of pulmonary emphysema. Egyptian Journal of Chest Diseases and Tuberculosis 2016;65(1):71‐9.
Cardoso 2007 {published data only}
    1. Cardoso PFG, Snell GI, Hopkins P, Sybrecht GW, Stamatis G, Ng AW, et al. Clinical application of airway bypass with paclitaxel‐eluting stents: early results. Journal of Thoracic and Cardiovascular Surgery 2007;134(4):974‐81. - PubMed
Choong 2005 {published data only}
    1. Choong CK, Haddad FJ, Gee EY, Cooper JD. Feasibility and safety of airway bypass stent placement and influence of topical mitomycin C on stent patency. Journal of Thoracic and Cardiovascular Surgery 2005;129(3):632‐8. - PubMed
Choong 2006 {published data only}
    1. Choong CK, Phan L, Massetti P, Haddad FJ, Martinez C, Roschak E, et al. Prolongation of patency of airway bypass stents with use of drug‐eluting stents. Journal of Thoracic and Cardiovascular Surgery 2006;131(1):60‐4. - PubMed
Choong 2008 {published data only}
    1. Choong CK, Macklem PT, Pierce JA, Das N, Lutey BA, Martinez CO, et al. Airway bypass improves the mechanical properties of explanted emphysematous lungs. American Journal of Respiratory and Critical Care Medicine 2008;178(9):902‐5. - PMC - PubMed
Criner 2009 {published data only}
    1. Criner GJ, Pinto‐Plata V, Strange C, Dransfield M, Gotfried M, Leeds W, et al. Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results. American Journal of Respiratory and Critical Care Medicine 2009;179(9):791‐8. [DOI: 10.1164/rccm.200810-1639OC] - DOI - PubMed
De Oliveira 2006 {published data only}
    1. Oliveira HG, Macedo‐Neto AV, John AB, Jungblut S, Prolla JC, Menna‐Barreto SS, et al. Transbronchoscopic pulmonary emphysema treatment: 1‐month to 24‐month endoscopic follow‐up. Chest 2006;130(1):190‐9. - PubMed
Deslee 2014 {published data only}
    1. Deslee G, Klooster K, Hetzel M, Stanzel F, Kessler R, Marquette CH, et al. Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial. Thorax 2014;69(11):980‐6. - PMC - PubMed
Emery 2010 {published data only}
    1. Emery MJ, Eveland RL, Eveland K, Couetil LL, Hildebrandt J, Swenson ER. Lung volume reduction by bronchoscopic administration of steam. American Journal of Respiratory and Critical Care Medicine 2010;182(10):1282‐91. - PubMed
Faisal 2016 {published data only}
    1. Faisal A, Zoumot Z, Shah PL, Neder JA, Polkey MI, Hopkinson NS. Effective bronchoscopic lung volume reduction accelerates exercise oxygen uptake kinetics in emphysema. Chest 2016;149(2):435‐46. - PubMed
Falkenstern‐Ge 2013 {published data only}
    1. Falkenstern‐Ge RF, Ingerl H, Kohlhäufl M. Severe emphysema treated by endoscopic bronchial volume reduction with lung sealant (AeriSeal). Case Reports in Pulmonology 2013;2013:.. [DOI: 10.1155/2013/361391] - DOI - PMC - PubMed
Fann 2003 {published data only}
    1. Fann JI, Berry GJ, Burdon TA. Bronchoscopic approach to lung volume reduction using a valve device. Journal of Bronchology and Interventional Pulmonology 2003;10(4):253‐9.
Fruchter 2016 {published data only}
    1. Fruchter O, Rosengarten D, Goldberg E, Ben‐Zvi H, Tor R, Kramer MR. Airway bacterial colonization and serum C‐reactive protein are associated with chronic obstructive pulmonary disease exacerbation following bronchoscopic lung volume reduction. Clinical Respiratory Journal 2016;10(2):239‐45. [DOI: 10.1111/crj.12211] - DOI - PubMed
Gompelmann 2010 {published data only}
    1. Gompelmann D, Eberhardt R, Michaud G, Ernst A, Herth FJ. Predicting atelectasis by assessment of collateral ventilation prior to endobronchial lung volume reduction: a feasibility study. Respiration 2010;80(5):419‐25. - PubMed
Gompelmann 2012 {published data only}
    1. Gompelmann D, Heussel CP, Eberhardt R, Snell G, Hopkins P, Baker K, et al. Efficacy of bronchoscopic thermal vapor ablation and lobar fissure completeness in patients with heterogeneous emphysema. Respiration 2012;83(5):400‐6. [DOI: 10.1159/000336239] - DOI - PubMed
Gompelmann 2013 {published data only}
    1. Gompelmann D, Eberhardt R, Ernst A, Hopkins P, Egan J, Stanzel F, et al. The localized inflammatory response to bronchoscopic thermal vapor ablation. Respiration 2013;86(4):324‐31. [DOI: 10.1159/000354175] - DOI - PubMed
Hartman 2015 {published data only}
    1. Hartman JE, Klooster K, Gortzak K, Hacken NH, Slebos DJ. Long‐term follow‐up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema. Respirology 2015;20(2):319‐26. - PMC - PubMed
Herth 2010 {published data only}
    1. Herth FJF, Eberhard R, Gompelmann D, Slebos D‐J, Ernst A. Bronchoscopic lung volume reduction with a dedicated coil: a clinical pilot study. Therapeutic Advances in Respiratory Disease 2010;4(4):225‐31. [DOI: 10.1177/1753465810368553] - DOI - PubMed
Herth 2011 {published data only}
    1. Herth FJF, Gompelmann D, Stanzel F, Bonnet R, Behr J, Schmidt B, et al. Treatment of advanced emphysema with emphysematous lung sealant (AeriSeal). Respiration 2011;82(1):36‐45. [DOI: 10.1159/000322649] - DOI - PubMed
Herth 2012 {published data only}
    1. Herth FJ, Ernst A, Baker KM, Egan JJ, Gotfried MH, Hopkins P, et al. Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema. International Journal of Chronic Obstructive Pulmonary Disease 2012;7:397‐405. - PMC - PubMed
Hopkinson 2005 {published data only}
    1. Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. American Journal of Respiratory Critical Care Medicine 2005;171(5):453‐60. - PubMed
Hopkinson 2011 {published data only}
    1. Hopkinson NS, Kemp SV, Toma TP, Hansell DM, Geddes DM, Shah PL, et al. Atelectasis and survival after bronchoscopic lung volume reduction for COPD. European Respiratory Journal 2011;37(6):1346‐51. - PubMed
Klooster 2014 {published data only}
    1. Klooster K, Hacken NHT, Franz I, Kerstjens HAM, Rikxoort EM, Slebos D‐J. Lung volume reduction coil treatment in chronic obstructive pulmonary disease patients with homogeneous emphysema: a prospective feasibility trial. Respiration 2014;88(2):116‐25. [DOI: 10.1159/000362522] - DOI - PubMed
Kontogianni 2014 {published data only}
    1. Kontogianni K, Gerovasili V, Gompelmann D, Schuhmann M, Heussel CP, Herth FJ, et al. Effectiveness of endobronchial coil treatment for lung volume reduction in patients with severe heterogeneous emphysema and bilateral incomplete fissures: a six‐month follow‐up. Respiration 2014;88(1):52‐60. - PubMed
Kotecha 2011 {published data only}
    1. Kotecha S, Westall GP, Holsworth L, Pham A, Williams TJ, Snell GI. Long‐term outcomes from bronchoscopic lung volume reduction using a bronchial prosthesis. Respirology 2011;16(1):167‐73. - PubMed
Kramer 2012 {published data only}
    1. Kramer MR, Refaely Y, Maimon N, Rosengarten D, Fruchter O. Bilateral endoscopic sealant lung volume reduction therapy for advanced emphysema. Chest 2012;142(5):1111‐7. - PubMed
    1. Kramer MR, Refaely Y, Maimon N, Rosengarten D, Fruchter O. Two‐year follow‐up in patients treated with emphysematous lung sealant for advanced emphysema. Chest 2013;144(5):1677‐80. [DOI: 10.1378/chest.13-0446.] - DOI - PubMed
Kramer 2013 {published data only}
    1. Kramer MR, Fruchter O, Eberhardt R, Valipour A, Assadi S, Bonnet R, et al. Emphysematous lung sealant therapy attenuates the chronic inflammatory state of advanced emphysema. Journal of Pulmonary & Respiratory Medicine 2013;3(5):1‐5. [DOI: 10.4172/2161-105X.1000163] - DOI
Magnussen 2012 {published data only}
    1. Magnussen H, Kramer MR, Kirsten AM, Marquette C, Valipour A, Stanzel F, et al. Effect of fissure integrity on lung volume reduction using a polymer sealant in advanced emphysema. Thorax 2012;67(4):302‐8. - PubMed
Pizarro 2015 {published data only}
    1. Pizarro C, Ahmadzadehfar H, Essler M, Tuleta I, Fimmers R, Nickenig G, et al. Effect of endobronchial valve therapy on pulmonary perfusion and ventilation distribution. PLOS One 2015;10(3):e0118976. - PMC - PubMed
Refaely 2010 {published data only}
    1. Refaely Y, Dransfield M, Kramer MR, Gotfried M, Leeds W, McLennan G, et al. Biologic lung volume reduction therapy for advanced homogeneous emphysema. European Respiratory Journal 2010;36(1):20‐7. - PubMed
Reilly 2007 {published data only}
    1. Reilly J, Washko G, Pinto‐Plata V, Velez E, Kenney L, Berger R, et al. Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. Chest 2007;131(4):1108‐13. - PubMed
Rendina 2003 {published data only}
    1. Rendina EA, Giacomo T, Venuta F, Coloni GF, Meyers BF, Patterson GA, et al. Feasibility and safety of the airway bypass procedure for patients with emphysema. Journal of Thoracic and Cardiovascular Surgery 2003;125(6):1294‐7. - PubMed
Slebos 2012 {published data only}
    1. Slebos DJ, Klooster K, Ernst A, Herth FJ, Kerstjens HA. Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneous emphysema. Chest 2012;142(3):574‐82. - PubMed
Snell 2003 {published data only}
    1. Snell GI, Holsworth L, Borrill ZL, Thomson KR, Kalff V, Smith JA, et al. The potential for bronchoscopic lung volume reduction using bronchial prostheses. Chest 2003;124(3):1073‐80. - PubMed
Snell 2009 {published data only}
    1. Snell GI, Hopkins P, Westall G, Holsworth L, Carle A, Williams TJ. A feasibility and safety study of bronchoscopic thermal vapor ablation: a novel emphysema therapy. Annals of Thoracic Surgery 2009;88(6):1993‐8. - PubMed
Snell 2012 {published data only}
    1. Snell G, Herth FJ, Hopkins P, Baker KM, Witt C, Gotfried MH, et al. Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema. European Respiratory Journal 2012;39(6):1326‐33. - PubMed
Springmeyer 2009 {published data only}
    1. Springmeyer SC, Bolliger CT, Waddell TK, Gonzalez X, Wood DE, Teams IBVVPTR. Treatment of heterogeneous emphysema using the Spiration IBV valves. Thoracic Surgery Clinics 2009;19(2):247‐53, ix‐x. - PubMed
Toma 2003 {published data only}
    1. Toma TP, Hopkinson NS, Hillier J, Hansell DM, Morgan C, Goldstraw PG, et al. Bronchoscopic volume reduction with valve implants in patients with severe emphysema. Lancet 2003;361(9361):931‐3. - PubMed
Venuta 2005 {published data only}
    1. Venuta F, Anile M, Diso D, Carillo C, Giacomo T, D'Andrilli A, et al. Long‐term follow‐up after bronchoscopic lung volume reduction in patients with emphysema. European Respiratory Journal 2012;39(5):1084‐9. - PubMed
    1. Venuta F, Giacomo T, Rendina EA, Ciccone AM, Diso D, Perrone A, et al. Bronchoscopic lung‐volume reduction with one‐way valves in patients with heterogenous emphysema. Annals of Thoracic Surgery 2005;79(2):411‐6; discussion 6‐7. - PubMed
Venuta 2011 {published data only}
    1. Venuta F, Diso D, Anile M, Giacomo T, Rendina EA, Rolla M, et al. Bronchoscopic lung volume reduction as a bridge to lung transplantation in patients with chronic obstructive pulmonary disease. European Journal Cardio‐Thoracic Surgery 2011;39(3):364‐7. [DOI: 10.1016/j.ejcts.2010.06.005] - DOI - PubMed
Wan 2006 {published data only}
    1. Wan IY, Toma TP, Geddes DM, Snell G, Williams T, Venuta F, et al. Bronchoscopic lung volume reduction for end‐stage emphysema: report on the first 98 patients. Chest 2006;129(3):518‐26. - PubMed
Wood 2007 {published data only}
    1. Wood DE, McKenna RJ, Yusen RD, Sterman DH, Ost DE, Springmeyer SC, et al. A multicenter trial of an intrabronchial valve for treatment of severe emphysema. Journal of Thoracic and Cardiovascular Surgery 2007;133(1):65‐73. [DOI: 10.1016/j.jtcvs.2006.06.051] - DOI - PubMed
Yim 2004 {published data only}
    1. Yim AP, Hwong TM, Lee TW, Li WW, Lam S, Yeung TK, et al. Early results of endoscopic lung volume reduction for emphysema. Journal of Thoracic and Cardiovascular Surgery 2004;127(6):1564‐73. - PubMed

References to ongoing studies

ISRCTN19684749 {published data only}
    1. ISRCTN19684749. The CELEB trial: comparative effectiveness of lung volume reduction surgery for emphysema and bronchoscopic lung volume reduction with valve placement. www.isrctn.com/ISRCTN19684749 (accessed 23 May 2016). - PMC - PubMed
NCT01457833 {published data only}
    1. NCT01457833. Implantation of endobronchial valves versus intrabronchial valves in patients with severe heterogeneous emphysema. clinicaltrials.gov/ct2/show/NCT01457833 (accessed 19 October 2011).
NCT01796392 {published data only}
    1. NCT01796392. Pulmonx endobronchial valves used in treatment of emphysema (LIBERATE Study). clinicaltrials.gov/ct2/show/record/NCT01796392 (accessed 20 February 2013).
NCT01812447 {published data only}
    1. NCT01812447. Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function (EMPROVE). clinicaltrials.gov/ct2/show/record/NCT01812447 (accessed 7 March 2013).
NCT01989182 {published data only}
    1. Li S, Wang G, Wang C, Jin F, Gao X, Yang H, et al. LATE‐BREAKING ABSTRACT: The REACH study, a randomized controlled trial assessing the safety and effectiveness of the spiration valve system intra‐bronchial therapy for severe emphysema. European Respiratory Journal 2016;48:OA3013.
    1. NCT01989182. The spiration valve system for the treatment of severe emphysema. clinicaltrials.gov/ct2/show/record/NCT01989182 (accessed 6 November 2013).
NCT02022683 {published data only}
    1. NCT02022683. To improve lung function and symptoms for emphysema patients Using Zephyr EBV (TRANSFORM). clinicaltrials.gov/ct2/show/record/NCT02022683 (accessed 17 December 2013).
NCT02823223 {published data only}
    1. NCT02823223. Endobronchial valve in patients With heterogeneous emphysema. clinicaltrials.gov/ct2/show/record/NCT02823223 (accessed 29 June 2016).

Additional references

Agzarian 2013
    1. Agzarian J, Miller JD, Kosa SD, Malthaner R, Tan L, Canadian Volume Reduction Surgery Study Group. Long‐term survival analysis of the Canadian lung volume reduction surgery trial. Annals of Thoracic Surgery 2013;96(4):1217‐22. [DOI: 10.1016/j.athoracsur.2013.04.077.] - DOI - PubMed
Aljuri 2009
    1. Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation before endobronchial lung volume reduction. Applied Physiology 2009;106(3):774‐83. [DOI: 10.3109/15412555.2015.1115007] - DOI - PubMed
Ambrosino 1999
    1. Ambrosino N. Field tests in pulmonary disease. Thorax 1999;54(3):191‐3. [DOI: 10.1136/thx.54.3.191] - DOI - PMC - PubMed
Bagdonas 2015
    1. Bagdonas E, Raudoniute J, Bruzauskaite I, Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. International Journal of Chronic Obstructive Pulmonary Disease 2015;10:995‐1013. [DOI: 10.2147/COPD.S82518] - DOI - PMC - PubMed
Biederer 2012
    1. Biederer J, Beer M, Hirsch W, Wild J, Fabel M, Puderbach M, et al. MRI of the lung (2/3). Why … when … how?. Insights Imaging 2012;3(4):355‐71. [DOI: 10.1007/s13244-011-0146-8] - DOI - PMC - PubMed
Bourdin 2009
    1. Bourdin A, Burgel PR, Chanez P, Garcia G, Perez T, Roche N. Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. European Respiratory Review 2009;18(114):198‐212. [DOI: 10.1183/09059180.00005509] - DOI - PubMed
Boutou 2013
    1. Boutou AK, Shrikrishna D, Tanner RJ, Smith C, Kelly JL, Ward SP, et al. Lung function indices for predicting mortality in COPD. European Respiratory Journal 2013;42(3):616‐25. [DOI: 10.1183/09031936.00146012] - DOI - PMC - PubMed
Boutou 2015
    1. Boutou AK, Zoumot Z, Nair A, Davey C, Hansell DM, Jamurtas A, et al. The impact of homogeneous versus heterogeneous emphysema on dynamic hyperinflation in patients with severe COPD assessed for lung volume reduction. Journal of Chronic Obstructive Pulmonary Disease 2015;12(6):598‐605. [DOI: 10.3109/15412555.2015.1020149] - DOI - PMC - PubMed
Campbell 2000
    1. Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised trials. Journal of Health Services Research & Policy 2000;5(1):12‐16. - PubMed
Cavaillès 2013
    1. Cavaillès A, Brinchault‐Rabin G, Dixmier A, Goupil F, Gut‐Gobert C, Marchand‐Adam S, et al. Comorbidities of COPD. European Respiratory Review 2013;22(130):454‐75. [DOI: 10.1183/09059180.00008612] - DOI - PMC - PubMed
Cazzola 2008
    1. Cazzola M, MacNee W, Martinez FJ, Rabe Klaus F, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal 2008;31(2):416‐69. [DOI: 10.1183/09031936.00099306] - DOI - PubMed
Celli 2007
    1. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal 2007;29(6):1224‐38. [DOI: 10.1183/09031936.00109906] - DOI - PubMed
Cetti 2006
    1. Cetti EJ, Moore AJ, Geddes DM. Collateral ventilation. Thorax 2006;61(5):371‐3. [DOI: 10.1136/thx.2006.060509] - DOI - PMC - PubMed
Clark 2014
    1. Clark SJ, Zoumot Z, Bamsey O, Polkey MI, Dusmet M, Lim E, et al. Surgical approaches for lung volume reduction in emphysema. Clinical Medicine 2014;14(2):122‐7. [DOI: 10.7861/clinmedicine.] - DOI - PMC - PubMed
Cooper 1995
    1. Cooper JD, Trulock EP, Triantafillou AN, Patterson GA, Pohl MS, Deloney RN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. Journal of Thoracic and Cardiovascular Surgery 1995;109(1):106‐19. - PubMed
Cooper 2010
    1. Cooper JD. "All that glitters": evaluating interventions for emphysema. Chest 2010;138(2):243‐5. - PubMed
Criner 2008
    1. Criner GJ, Sternberg AL. National Emphysema Treatment Trial: the major outcomes of lung volume reduction surgery in severe emphysema. Proceedings of the American Thoracic Society 2008;5(4):393‐405. [DOI: 10.1513/pats.200801-013ET] - DOI - PMC - PubMed
Criner 2011
    1. Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The National Emphysema Treatment Trial (NETT) part II: lessons learned about lung volume reduction surgery. American Journal of Respiratory and Critical Care Medicine 2011;184(8):881‐93. - PMC - PubMed
Dal 2008
    1. Dal Negro R. Optimizing economic outcomes in the management of COPD. International Journal of Chronic Obstructive Pulmonary Disease 2008;3(1):1‐10. [PUBMED: PMC2528207] - PMC - PubMed
Demedts 2006
    1. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respiratory Research 2006;7(1):53. [DOI: 10.1186/1465-9921-7-53] - DOI - PMC - PubMed
Donohue 2005
    1. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005;2(1):111‐24. - PubMed
Eberhardt 2015
    1. Eberhardt R, Gompelmann D, Herth FJF, Schuhmann M. Endoscopic bronchial valve treatment: patient selection and special considerations. International Journal of Chronic Obstructive Pulmonary Disease 2015;10:2147. [DOI: 10.2147/COPD.S63473] - DOI - PMC - PubMed
Ferguson 2006
    1. Ferguson GT. Why does the lung hyperinflate?. Proceedings of the American Thoracic Society 2006;3(2):176‐9. [DOI: 10.1513/pats.200508-094DO] - DOI - PubMed
Fessler 1998
    1. Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. American Journal of Respiratory and Critical Care Medicine 1998;157(3):715‐22. [DOI: 10.1164/ajrccm.157.3.9608004] - DOI - PubMed
Fessler 2002
    1. Fessler HE, Scharf SM, Permutt S. Improvement in spirometry following lung volume reduction surgery: application of a physiologic model. American Journal of Respiratory and Critical Care Medicine 2002;165(1):34‐40. - PubMed
Fessler 2005
    1. Fessler HE. Collateral ventilation, the bane of bronchoscopic volume reduction. American Journal of Respiratory and Critical Care Medicine 2005;171(5):423‐4. - PubMed
Fessler 2008
    1. Fessler HE, Scharf SM, Ingenito EP, McKenna RJ Jr, Sharafkhaneh A. Physiologic basis for improved pulmonary function after lung volume reduction. Proceedings of the American Thoracic Society 2008;5(4):416‐20. [DOI: 10.1513/pats.200708-117ET] - DOI - PMC - PubMed
Galluccio 2010
    1. Galluccio G, Lucantoni G. Bronchoscopic lung volume reduction for pulmonary emphysema: preliminary experience with a new NOVATECHÂ endobronchial silicone one‐way valve. Interactive CardioVascular and Thoracic Surgery 2010;11(2):213‐5. [DOI: 10.1510/icvts.2010.236398] - DOI - PubMed
Garner 2016
    1. Garner J, Kemp SV, Toma TP, Hansell DM, Polkey MI, Shah PL, et al. Survival after endobronchial valve placement for emphysema: a 10‐year follow‐up study. American Journal of Respiratory and Critical Care Medicine 2016;194(4):519‐21. - PMC - PubMed
Ginsburg 2011
    1. Ginsburg ME, Thomashow BM, Yip CK, DiMango AM, Maxfield RA, Bartels MN, et al. Lung volume reduction surgery using the NETT selection criteria. Annals of Thoracic Surgery 2011;91(5):1556‐61. [DOI: 10.1016/j.athoracsur.2011.01.054] - DOI - PubMed
GOLD
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. http://www.goldcopd.org/ (accessed 2 February 2016).
Gompelmann 2014
    1. Gompelmann D, Herth FJF, Slebos DJ, Valipour A, Ernst A, Criner GJ, et al. Pneumothorax following endobronchial valve therapy and its impact on clinical outcomes in severe emphysema. Respiration 2014;87(6):485‐91. - PubMed
Gompelmann 2014a
    1. Gompelmann D, Eberhardt R, Herth F. Endoscopic volume reduction in COPD ‐ a critical review. Deutsches Ärzteblatt International 2014;111(49):827‐33. - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 2 February 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Hartman 2012
    1. Hartman JE, Hacken NHT, Klooster K, Boezen HM, Greef MHG, Slebos D‐J. The minimal important difference for residual volume in patients with severe emphysema. European Respiratory Journal 2012;40(5):1137‐41. [DOI: 10.1183/09031936.00219111] - DOI - PubMed
Herth 2013
    1. Herth FJF, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, et al. Radiological and clinical outcomes of using Chartis to plan endobronchial valve treatment. European Respiratory Journal 2013;41(2):302‐8. - PubMed
Herth 2016
    1. Herth FJF, Slebos D‐J, Rabe KF, Shah PL. Endoscopic lung volume reduction: an expert panel recommendation. Respiration 2016;91(3):241‐50. [DOI: 10.1159/000444090] - DOI - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. available from www.handbook.cochrane.org.
Higuchi 2006
    1. Higuchi T, Reed A, Oto T, Holsworth L, Ellis S, Bailey MJ, et al. Relation of interlobar collaterals to radiological heterogeneity in severe emphysema. Thorax 2006;61(5):409‐13. [DOI: 10.1136/thx.2005.051219] - DOI - PMC - PubMed
Hogg 2004
    1. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364(9435):709‐21. - PubMed
Ingenito 2001
    1. Ingenito EP, Reilly JJ, Mentzer SJ, Swanson SJ, Vin R, Keuhn H, et al. Bronchoscopic volume reduction: a safe and effective alternative to surgical therapy for emphysema. American Journal of Respiratory and Critical Care Medicine 2001;164(2):295‐301. - PubMed
Ingenito 2005
    1. Ingenito EP, Tsai LW, Majumdar A, Suki B. On the role of surface tension in the pathophysiology of emphysema. American Journal of Respiratory and Critical Care Medicine 2005;171(4):300‐4. [DOI: 10.1164/rccm.200406-770PP] - DOI - PubMed
Ingenito 2008
    1. Ingenito EP, Wood DE, Utz JP. Bronchoscopic lung volume reduction in severe emphysema. Proceedings of the American Thoracic Society 2008;5(4):454‐60. [DOI: 10.1513/pats.200707‐085ET] - PMC - PubMed
Jones 2005
    1. Jones PW. St. George's respiratory questionnaire: MCID. COPD 2005;2(1):75‐9. - PubMed
Kim 2008
    1. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2008;5(4):478‐85. [PUBMED: 18453359] - PMC - PubMed
Kirkham 2013
    1. Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest 2013;144(1):266‐73. [DOI: 10.1378/chest.12-2664] - DOI - PubMed
Klooster 2014a
    1. Klooster K, Hacken NHT, Slebos D‐J. The lung volume reduction coil for the treatment of emphysema: a new therapy in development. Expert Review of Medical Devices 2014;11(5):481‐9. [DOI: 10.1586/17434440.2014.929490] - PubMed
Koster 2016
    1. Koster TD, Slebos D‐J. The fissure: interlobar collateral ventilation and implications for endoscopic therapy in emphysema. International Journal of Chronic Obstructive Pulmonary Disease 2016;11:765. [DOI: 10.2147/COPD.S103807] - DOI - PMC - PubMed
Lausberg 2003
    1. Lausberg HF, Chino K, Patterson GA, Meyers BF, Toeniskoetter PD, Cooper JD. Bronchial fenestration improves expiratory flow in emphysematous human lungs. Annals of Thoracic Surgery 2003;75(2):393‐8. - PubMed
Lozano 2013
    1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380(9859):2095‐128. [DOI: 10.1016/S0140-6736(12)61728-0] - DOI - PMC - PubMed
Macklin 1999
    1. Macklin R. The ethical problems with sham surgery in clinical research. New England Journal of Medicine 1999;341(13):992‐6. [DOI: 10.1056/NEJM199909233411312] - DOI - PubMed
Mair 2009
    1. Mair G, Miller JJ, McAllister D, Maclay J, Connell M, Murchison JT, et al. Computed tomographic emphysema distribution: relationship to clinical features in a cohort of smokers. European Respiratory Journal 2009;33(3):536‐42. [DOI: 10.1183/09031936.00111808] - DOI - PubMed
Mannino 2007
    1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370(9589):765‐73. [DOI: 10.1016/S0140-6736(07)61380-4] - DOI - PubMed
Mannino 2007a
    1. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2007;4(7):502‐6. [DOI: 10.1513/pats.200701-001FM] - DOI - PubMed
Maxfield 2004
    1. Maxfield RA. New and emerging minimally invasive techniques for lung volume reduction. Chest 2004;125(2):777‐83. - PubMed
McCarthy 2015
    1. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD003793.pub3] - DOI - PMC - PubMed
McNulty 2014
    1. McNulty W, Jordan S, Hopkinson NS. Attitudes and access to lung volume reduction surgery for COPD: a survey by the British Thoracic Society. BMJ Open Respiratory Research 2014;1(1):e000023. [DOI: 10.1136/bmjresp-2014-000023] - DOI - PMC - PubMed
Milanese 2016
    1. Milanese G, Silva M, Sverzellati N. Lung volume reduction of pulmonary emphysema: the radiologist task. Current Opinion in Pulmonary Medicine 2016;22(2):179‐86. [DOI: 10.1097/MCP.0000000000000252] - DOI - PubMed
Miller 2004
    1. Miller FG, Kaptchuk TJ. Sham procedures and the ethics of clinical trials. Journal of the Royal Society of Medicine 2004;97(12):576‐8. - PMC - PubMed
Miller 2006
    1. Miller JD, Malthaner RA, Goldsmith CH, Goeree R, Higgins D, Cox PG, et al. A randomized clinical trial of lung volume reduction surgery versus best medical care for patients with advanced emphysema: a two‐year study from Canada. Annals of Thoracic Surgery 2006;81(1):314‐21. [PUBMED: 16368389] - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLOS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] - DOI - PMC - PubMed
Mura 2005
    1. Mura M, Zompatori M, Mussoni A, Fasano L, Pacilli AMG, Ferro O, et al. Bullous emphysema versus diffuse emphysema: a functional and radiologic comparison. Respiratory Medicine 2005;99(2):171‐8. [DOI: 10.1016/j.rmed.2004.06.010] - DOI - PubMed
Naunheim 2006
    1. Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, et al. Long‐term follow‐up of patients receiving lung‐volume‐reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Annals of Thoracic Surgery 2006;82(2):431‐43. - PubMed
NETT 2001
    1. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung‐volume‐reduction surgery. New England Journal of Medicine 2001;345(15):1075. [DOI: 10.1056/NEJMoa11798] - DOI - PubMed
NICE 2010
    1. The National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. https://www.nice.org.uk/guidance/cg101 (accessed 15 April 2016). - PubMed
Papandrinopoulou 2012
    1. Papandrinopoulou D, Tzouda V, Tsoukalas G. Lung compliance and chronic obstructive pulmonary disease. Pulmonary Medicine 2012;2012:1‐6. [DOI: 10.1155/2012/542769] - DOI - PMC - PubMed
Park 2015
    1. Park TS, Hong Yi, Lee JS, Oh SY, Lee SM, Kim N, et al. Bronchoscopic lung volume reduction by endobronchial valve in advanced emphysema: the first Asian report. International Journal of Chronic Obstructive Pulmonary Disease 2015;10:1501. [DOI: 10.2147/COPD.S85744] - DOI - PMC - PubMed
Perera 2012
    1. Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. Journal of Chronic Obstructive Pulmomary Disease 2012;9(2):131‐41. [DOI: 10.3109/15412555.2011.650239] - DOI - PubMed
Pompeo 2012
    1. Pompeo E, Rogliani P, Tacconi F, Dauri M, Saltini C, Novelli G, et al. Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. Journal of Thoracic and Cardiovascular Surgery 2012;143(1):47‐54. [DOI: 10.1016/j.jtcvs.2011.09.050.] - DOI - PubMed
Puhan 2011
    1. Puhan MA, Gimeno‐Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD005305.pub3] - DOI - PubMed
Puhan 2011a
    1. Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, et al. The minimal important difference of exercise tests in severe COPD. European Respiratory Journal 2011;37(4):784‐90. [DOI: 10.1183/09031936.00063810.] - DOI - PMC - PubMed
Ramsey 2007
    1. Ramsey SD, Shroyer AL, Sullivan SD, Wood DE. Updated evaluation of the cost‐effectiveness of lung volume reduction surgery. Chest 2007;131(3):823‐32. - PubMed
Rathinam 2014
    1. Rathinam S, Oey I, Steiner M, Spyt T, Morgan MD, Waller DA. The role of the emphysema multidisciplinary team in a successful lung volume reduction surgery programme. European Journal of Cardio‐Thoracic Surgery 2014;46(6):1021‐6. - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schuhmann 2015
    1. Schuhmann M, Raffy P, Yin Y, Gompelmann D, Oguz I, Eberhardt R, et al. Computed tomography predictors of response to endobronchial valve lung reduction treatment. Comparison with Chartis. American Journal of Respiratory and Critical Care Medicine 2015;191(7):767‐74. - PubMed
Shah 2014
    1. Shah PL, Herth FJF. Current status of bronchoscopic lung volume reduction with endobronchial valves. Thorax 2014;69(3):280‐6. - PubMed
Sharafkhaneh 2008
    1. Sharafkhaneh A, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proceedings of the American Thoracic Society 2008;5(4):475‐7. [DOI: 10.1513/pats.200708-126ET] - DOI - PMC - PubMed
Stockley 2009
    1. Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2009;6(6):524‐6. [DOI: 10.1513/pats.200904-016DS] - DOI - PubMed
Storbeck 2015
    1. Storbeck B, Schröder TH, Oldigs M, Rabe KF, Weber C. Emphysema: imaging for endoscopic lung volume reduction [Lungenemphysem: Bildgebung bei endoskopischerLungenvolumenreduktion]. Fortschritte auf dem Gebiet der Röntgenstrahlen und bildgebenden Verfahren 2015;187:543‐54. [DOI: 10.1055/s-0034-1399424] - DOI - PubMed
Suki 2003
    1. Suki B, Lutchen KR, Ingenito EP. On the progressive nature of emphysema: roles of proteases, inflammation, and mechanical forces. American Journal of Respiratory and Critical Care Medicine 2003;168(5):516‐21. [DOI: 10.1164/rccm.200208-908PP] - DOI - PubMed
Taraseviciene‐Stewart 2008
    1. Taraseviciene‐Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. Journal of Clinical Investigation 2008;118(2):394‐402. [DOI: 10.1172/JCI31811] - DOI - PMC - PubMed
Terry 1978
    1. Terry PB, Traystman RJ, Newball HH, Batra G, Menkes HA. Collateral ventilation in man. New England Journal of Medicine 1978;298(1):10‐15. - PubMed
Tuder 2003
    1. Tuder RM, McGrath S, Neptune E. The pathobiological mechanisms of emphysema models: what do they have in common?. Pulmonary Pharmacology and Therapeutics 2003;16(2):67‐78. - PubMed
Valipour 2015
    1. Valipour A, Shah PL, Gesierich W, Eberhardt R, Snell G, Strange C, et al. Patterns of emphysema heterogeneity. Respiration 2015;90(5):402‐11. - PMC - PubMed
Van Agteren 2016
    1. Agteren JEM, Carson, KV, Tiong LU, Smith BJ. Lung volume reduction surgery for diffuse emphysema. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD001001.pub3; CD001001] - DOI - PMC - PubMed
Venuta 2006
    1. Venuta F, Rendina EA, Giacomo T, Anile M, Diso D, Andreetti C, et al. Bronchoscopic procedures for emphysema treatment. European Journal of Cardio‐thoracic Surgery 2006;29(3):281‐7. [DOI: 10.1016/j.ejcts.2005.12.009] - DOI - PubMed
Weder 1997
    1. Weder W, Thurnheer R, Stammberger U, Bürge M, Russi EW, Bloch KE. Radiologic emphysema morphology is associated with outcome after surgical lung volume reduction. Annals of Thoracic Surgery 1997;64(2):313‐20. - PubMed
Weder 2009
    1. Weder W, Tutic M, Bloch KE. Lung volume reduction surgery in nonheterogeneous emphysema. Thoracic Surgery Clinics 2009;19(2):193‐9. [DOI: 10.1016/j.thorsurg.2009.03.002] - DOI - PubMed
Wedzicha 2003
    1. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respiratory Care 2003;48(12):1204‐15. - PubMed
Wedzicha 2012
    1. Wedzicha JA, Decramer M, Seemungal TAR. The role of bronchodilator treatment in the prevention of exacerbations of COPD. European Respiratory Journal 2012;40(6):1545‐54. [DOI: 10.1183/09031936.00048912] - DOI - PMC - PubMed
Welling 2015
    1. Welling JBA, Hartman JE, Hacken NHT, Klooster K, Slebos D‐J. The minimal important difference for the St George's Respiratory Questionnaire in patients with severe COPD. European Respiratory Journal 2015;46(6):1598‐604. [DOI: 10.1183/13993003.00535-20151] - DOI - PubMed
Welte 2015
    1. Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. International Journal of Clinical Practice 2015;69(3):336‐49. [DOI: 10.1111/ijcp.12522] - DOI - PubMed
Zeng 2012
    1. Zeng G, Sun B, Zhong N. Non‐smoking‐related chronic obstructive pulmonary disease: A neglected entity?. Respirology 2012;17(6):908‐12. [DOI: 10.1111/j.1440-1843.2012.02152.x.] - DOI - PubMed
Zoumot 2014
    1. Zoumot Z, Jordan S, Hopkinson NS. Emphysema: time to say farewell to therapeutic nihilism. Thorax 2014;69(11):973‐5. [DOI: 10.1136/thoraxjnl-2014-205667] - DOI - PMC - PubMed
Zoumot 2015
    1. Zoumot Z, LoMauro A, Aliverti A, Nelson C, Ward S, Jordan S, et al. Lung volume reduction in emphysema improves chest wall asynchrony. Chest 2015;148(1):185‐95. [DOI: 10.1378/chest.14-2380] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources